Monday, June 17, 2013

Imprimis Pharmaceuticals Is Primed to Change an $11 Billion Dollar Industry By Ilana Greene - June 13, 2013

Biotechnology pharmaceutical companies are often problematic investment prospects due to the risks associated with the industry.  Technological valuations are sometimes overstated or based upon biased assumptions.  Additionally, revenue is difficult to forecast and supplementary costs linked with bringing pharmaceutical products to market are miscalculated or even overlooked.  Yet, strategic approaches to biotech pharmas can yield high ROIs when traders consider the full scope of the venture.  Variables such as clinical trial costs, milestone disbursements, and sales royalties can give investors valuable information enabling them to make profitable decisions.  A life science investment banking firm, BioGenectic Venture, states that the above and other factors are changing the minds of investors—casual and expert.  

continue to read here

No comments: